ReviewViruses2017
T Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal Models.
Review in Viruses, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Impact of synthetic and biological immunomodulatory therapy on the duration of 17DD yellow fever vaccine-induced immunity in rheumatoid arthritis.Arthritis research & therapy · 2019Trial
- Review
- Wesselsbron Virus-Induced Hepatitis in Ewes and Lambs Unraveled Through Machine Learning-Driven Digital Histopathology.Transboundary and emerging diseases · 2026Article
- Article
- Induction of systemic and mucosal immune response against Zika virus by vaccination with non-infectious chimeric VLPs.Scientific reports · 2025Article
- Review
- Yellow Fever: Global Impact, Epidemiology, Pathogenesis, and Integrated Prevention Approaches.Le infezioni in medicina · 2024Review
- The next frontier in vaccine design: blending immune correlates of protection into rational vaccine design.Current opinion in immunology · 2022Review
- Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases.Vaccine: X · 2022Article
- Article
- Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Yellow fever virus vaccination: an emblematic model to elucidate robust human immune responses.Human vaccines & immunotherapeutics · 2021Article
- Review
- Article
- A Yellow Fever Virus 17D Infection and Disease Mouse Model Used to Evaluate a Chimeric Binjari-Yellow Fever Virus Vaccine.Vaccines · 2020Article
- Review
- Review
- T Lymphocytes as Measurable Targets of Protection and Vaccination Against Viral Disorders.International review of cell and molecular biology · 2019Review
- Randomized, double-blinded, controlled non-inferiority trials evaluating the immunogenicity and safety of fractional doses of Yellow Fever vaccines in Kenya and Uganda.Wellcome open research · 2019Article
- Identification of Protective CD8 T Cell Responses in a Mouse Model of Zika Virus Infection.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The 17D line of yellow fever virus vaccines is among the most effective vaccines ever created. The humoral and cellular immunity elicited by 17D has been well characterized in humans. Neutralizing antibodies have long been known to provide protection against challenge with a wild-type virus. However, a well characterized T cell immune response that is robust, long-lived and polyfunctional is also elicited by 17D. It remains unclear whether this arm of immunity is protective following challenge with a wild-type virus. Here we introduce the 17D line of yellow fever virus vaccines, describe the current state of knowledge regarding the immunity directed towards the vaccines in humans and conclude with a discussion of animal models that are useful for evaluating T cell-mediated immune protection to yellow fever virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.